How the fetus withstands an environment of reduced oxygenation during life in the 3 womb has been a vibrant area of research since this field was introduced by Joseph 4
rate to baseline values by 30 minutes from the onset of acute hypoxia (Jones & 1 Ritchie, 1983) . Accordingly, fetal treatment with the beta blocker propranolol 2 prolongs the fetal bradycardic response to acute hypoxia (Court & Parer, 1984) . 3
The increase in catecholamines and other constrictor agents in the fetal circulation 4 also maintain the neurally-triggered peripheral vasoconstrictor response, not only 5 prolonging redistribution of the fetal cardiac output but helping maintain perfusion 6 pressure as the episode of acute hypoxia continues. Therefore, fetal treatment with 7 alpha-adrenergic or vasopressin receptor antagonists decrease the ability of the 8 fetus to maintain peripheral vascular resistance and arterial blood pressure during 9 acute hypoxia (Peréz et al. 1989 ; Giussani et al. 1993) . There is some evidence 10 that during periods of fetal oxygen deprivation the carotid chemoreflex is also 11 involved in affecting the release of catecholamines from the adrenal medulla 12 (Jensen & Hanson, 1995) and in sensitising the adrenal cortex to ACTH (Giussani et 13 al. 1994a) , enhancing the release of cortisol into the fetal circulation. By contrast, 14 the carotid chemoreceptors are not involved in the fetal plasma vasopressin or 15
angiotensin II response to acute hypoxia (Giussani et al. 1994b ; Green et al. 16 1998) . Some studies have implicated calcitonin gene related peptide (cGRP) as 17
having an important role in the activation of the sympathetic nervous system 18 during acute hypoxia in the late gestation fetus. It has been reported that 19 treatment of fetal sheep with cGRP antagonists markedly diminished the fetal 20 femoral vasoconstrictor and the plasma NPY and catecholamine responses to acute 21 hypoxia (Thakor et al. 2005) . 22 
23
It is also known that fetal carotid chemoreflex and endocrine constrictor influences 24 on the fetal peripheral circulations are opposed by hypoxia-induced increases in the 25 dilator gas nitric oxide (NO). Therefore, fetal treatment with the NO clamp, a 26 technique that permits de novo synthesis of NO to be blocked while maintaining 27 basal cardiovascular function (Gardner et al. 2001; 2002b; Gardner & Giussani, 1 2003) , revealed a significantly greater femoral vasoconstrictor response to acute 2 hypoxia in the late gestation fetus (Morrison et al. 2003) . More recently, in the last 3 few years, our group has made the discovery that the influence of NO at the level 4 of the fetal vasculature is itself limited by the generation of reactive oxygen species 5 (ROS) during acute hypoxia (Thakor et al. 2010b ). This, in essence, creates a 6 vascular oxidant tone that contributes to the regulation of blood flow in the fetal 7 circulation and one that can be manipulated in favour of constriction or dilatation by 8 altering the numerator or denominator of the fraction. Hence, treatment of the 9 sheep fetus with antioxidants, such as vitamin C (Thakor et al. 2010b ), allopurinol 10 (Kane et al. 2014), melatonin (Thakor et al. 2015) or agents that increase NO, such 11 as statins (Kane et al. 2012) , all shift the vasoactive balance in favour of dilatation, 12 thereby diminishing the fetal peripheral vasoconstrictor response to acute hypoxia. because, clinically, it is generally believed that basal placental and umbilical blood 23 flow in late gestation is maximal. This is clearly not true. 24 
25
Since fetal treatment with antioxidants diminishes the fetal peripheral 26 vasoconstrictor response to acute hypoxia, it has been suggested that fetal 27 exposure to antioxidants, for instance via maternal antioxidant supplementation, 1 might weaken the fetal brain sparing response to acute hypoxia (Thakor et under conditions of fetal exposure to antioxidants, maintenance of cerebral blood 8 flow might not be necessarily compromised. However, the fetal cardiovascular 9 strategy to defend itself against acute hypoxia may need to change to increase 10 cardiac output and maintain perfusion in the presence of a generalised dilator 11 response, akin, interestingly, to the response to acute hypoxia in the adult period 12 (Rowell & Blackmon, 1987; Marshall, 1999) . Furthermore, several studies have 13 dissociated the fetal peripheral vasoconstrictor and cerebral vasodilator responses 14 to acute hypoxia. For example, the magnitude of the increase in carotid blood flow 15 during acute hypoxia is similar in intact fetuses and in carotid sinus denervated 16 fetal sheep, despite an attenuated peripheral vasoconstriction and fetal brain 17 sparing ratio in the latter group (Giussani et al. 1993 ; Figure 1) . Similarly, the 18 magnitude of the increase in carotid blood flow (Giussani et al. 1993 ) and of the 19 decrease in the vascular resistance in the cerebral (Reuss et al. 1982 ) vascular 20 beds during acute hypoxia was similar in untreated fetuses and in fetuses treated 21 with α-adrenergic receptor antagonists, despite abolition of peripheral 22 vasoconstriction in the latter groups.
Therefore, while the fetal peripheral 23 vasoconstrictor response aids the redistribution of blood flow away from less 24 essential vascular beds, it is not indispensable at least to the maintenance of 25 carotid blood flow during acute hypoxia in the late gestation fetus. 26 
27
Maturation of the fetal brain sparing response to acute hypoxia 1 Prior to ca. 110 days of approximately a 150 day gestation, the sheep fetus has an 2 immature cardiovascular defence to acute hypoxic stress. This includes tachycardia 3 rather than bradycardia and an inability to increase peripheral vascular resistance 4 and maintain arterial blood pressure (Boddy et al. 1974; Iwamoto et al. 1989) . 5
After ca. 120 days of gestation, the pattern and the magnitude of the fetal heart 6 and circulatory responses to acute hypoxia change as the fetus approaches term, in 7 close temporal association with the prepartum increase in fetal plasma cortisol. As 8 the fetus approaches term, the bradycardic response to acute hypoxia switches 9 from being transient to becoming sustained and more pronounced (Fletcher et al. 10 2006) . In addition, the femoral vasoconstrictor response to acute hypoxia becomes 11 much greater with advancing gestation (Fletcher et al. 2006 ; Figure 3 ). The 12 physiology underlying the enhanced and sustained bradycardia in the term 13 compared with the preterm fetus includes maturation of carotid body chemoreflexes 14 and reciprocal changes in the responsiveness of fetal heart to autonomic agonists. 15
While fetal cardiac reactivity to muscarinic agonists increases, it decreases to β 1 -16 adrenergic stimulation, thereby promoting cardiac vagal dominance with increased 17 maturation (Fletcher et al. 2005; . Similarly, the greater increment in fetal 18 femoral vascular resistance during acute hypoxia with advancing gestational age 19 results, in part, from maturation of the carotid body chemoreflex and, in part, from 20 greater plasma catecholamine, vasopressin and neuropeptide Y responses (Fletcher 21 et al. 2006) .
During episodes of acute hypoxia, the adrenal output of 22 catecholamines may be stimulated both by the direct effects of hypoxia on the 23 gland and by neuronal stimulation (Jones et al. 1988) , especially following the 24 establishment of splanchnic nerve synapses with adrenal chromaffin cells at around 25 130 days of gestation (Boshier et al. 1989 ). The relative contribution of these two 26 stimuli in promoting adrenal catecholamine secretion during acute hypoxia also 27 changes with advancing gestation, reported both in the acutely-exteriorised, 1 anaesthetised fetal sheep preparation (Comline & Silver, 1961) and in the un-2 anaesthetised chronically instrumented fetal sheep preparation (Cheung, 1990) . 3
Comline & Silver (1961) studied the effects of splanchnic nerve section on the 4 outputs of adrenaline and noradrenaline from the adrenal gland in response to 5 asphyxia in pentobarbitone-anaesthetised fetal sheep from 80 days to term. The 6 degree of attenuation of the noradrenaline and adrenaline outputs following 7 splanchnic nerve section increased with advancing gestational age, suggesting an 8 increasing dependence of the adrenal medulla on innervation to respond to acute 9 oxygen deprivation.
In addition, it was shown that the adrenal outputs of 10 adrenaline and noradrenaline evoked by electrical stimulation of the splanchnic 11 nerves increased with advancing gestational age. The timing of the increase in 12 fetal adrenal noradrenaline content is coincident with an increase in adrenal 13 tyrosine hydroxylase mRNA levels and the onset of splanchnic innervation of the is separated from its splanchnic innervation and is perfused in vitro, it can also 25 respond directly to hypoxia even after 135 days (Adams et al. 1996) . While 26 information is available on the effects of gestational age on chemoreflex and 27 endocrine responses to acute hypoxia in the fetus, the contribution of alterations in 1 the vascular oxidant tone to the fetal brain sparing response during hypoxia with 2 advancing gestational age awaits investigation. 3
4
It is now also established that exposure of the preterm ovine fetus to synthetic 5 glucocorticoids, such as dexamethasone or betamethasone, administered in human 6
clinically-relevant doses, can switch the pattern and magnitude of the fetal heart 7 and circulatory responses to acute hypoxia in similar fashion to advancing 8 gestational age. Therefore, either fetal intravenous infusion with dexamethasone 9 for 48h to yield human clinically relevant circulating doses of the synthetic steroid, 10 or maternal intramuscular injection with a single course of dexamethasone of 2 x 11 12 mg 24h apart at 0.7-0.8 of gestation both switch the fetal heart and femoral 12 constrictor responses to acute hypoxia from the immature to the mature phenotype 13 antenatal glucocorticoid therapy not only accelerates fetal lung maturation but also 19 the capacity of the fetal cardiovascular system to respond to acute hypoxic stress. 20
21
An important point of related scientific and clinical interest is that the practise of 22 intra-partum electronic fetal monitoring (EFM) has been implemented worldwide for 23 several decades. Intra-partum EFM attempts to use changes in fetal heart rate 24 patterns to identify fetuses with a suspected hypoxic or asphyxic compromise in 25 order to deliver them before fetal cardiovascular collapse. Surprisingly, despite the 26 knowledge that advancing gestational age as well as antenatal glucocorticoid 27 therapy affects the magnitude and pattern of the fetal heart rate, fetal endocrine 1 and fetal metabolic responses to hypoxia (Fletcher et al. 2003 (Fletcher et al. , 2006 Clearly, investigation of the effects of gestational age and of antenatal 5 glucocorticoid therapy on the mechanisms mediating changes in fetal heart rate 6 variability is a highly significant area of urgently needed future clinical research. 7
8
The fetal brain sparing response during acute hypoglycaemia 9
Whether the carotid body can sense stimuli in addition to alterations in PO 2 , PCO 2 
10
and pH, such as glucose concentration, has been a matter of scientific interest for How adverse intrauterine conditions affect the capacity of the fetal cardiovascular 9 system to unleash a brain sparing response during an acute hypoxic insult has been 10 even less well studied because of the increasing layers of technological complexity 11 modelling these situations.
In adverse pregnancy, such as during placental 12 insufficiency or preeclampsia, it is generally accepted that the chronically 13 compromised fetus may not necessarily experience sustained, clamped reductions 14 in oxygenation but that it may be exposed to progressive hypoxia or repeated 15 periods of hypoxia and re-oxygenation or ischaemia and reperfusion, which are of 16 varying magnitude and duration. Consequently, a fetus in late gestation may be 17 exposed to acute hypoxia on a background of sustained reductions in fetal 18 oxygenation, what is commonly denominated acute-on-chronic hypoxia. 19
Alternatively, a fetus in late gestation may be exposed to acute hypoxia after a 20 period of chronic hypoxia has resolved, following normalisation of fetal oxygenation, 21 denominated acute-after-chronic hypoxia. How acute-on-chronic hypoxia or acute-22 after-chronic hypoxia affect the fetal brain sparing response has always been of 23 intense clinical and scientific interest, however the breadth and depth of 24 investigation to date have not matched this level of interest and these questions 25 remain to be systematically addressed. 26 
27
The few experimental studies modelling the effects on fetal cardiovascular function 1 of acute-on-chronic hypoxia include studies by Robinson et al. (1983) vasopressin and catecholamine responses to acute hypoxia were significantly 23 greater in chronically hypoxic relative to normoxic fetuses. These are similar 24 sensitising effects on cardiovascular and endocrine responses to acute hypoxia as 25 those determined in the fetal llama, a species adapted to the chronic hypoxia of life 26 at high altitude (Giussani et al. 1999) . It is also recognized that chronic hypoxia in 27 the fetus rarely occurs in isolation, and that, in adverse pregnancy, it is often 1 Clearly, the degree and duration of fetal acidosis is of paramount importance since 6 the development of severe fetal acidaemia (pH < 7.05) has been deemed as a key 7 turning point after which a large proportion of fetuses are unable to maintain 8 cardiovascular defence mechanisms to superimposed challenges, rendering them at 9 risk of asphyxial brain injury (Gunn & Bennet, 2009). 10
11
Only one study to date appears to have investigated the effects on fetal 12 cardiovascular function of acute-after-chronic hypoxia. In contrast to acute-on-13 chronic hypoxia, the technical advantage of the acute-after-chronic hypoxia model 14 is that both groups of control fetuses and fetuses pre-exposed to chronic hypoxia Clearly, these broad interpretations must now lay the foundation for future research 4 asking focused and mechanistic questions, which do not shy away from but rather 5 embrace the complexity of studying the cardiovascular function in vivo of the 6 chronically hypoxic fetus. 7 
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